Skip to main content
PMC home page
Journal of Neurology, Neurosurgery, and Psychiatry logoLink to Journal of Neurology, Neurosurgery, and Psychiatry
. 1999 Dec;67(6):758–762. doi: 10.1136/jnnp.67.6.758

The impact of molecular genetic analysis of the VHL gene in patients with haemangioblastomas of the central nervous system

S Glasker 1, B Bender 1, T Apel 1, E Natt 1, V van Velthoven 1, R Scheremet 1, J Zentner 1, H Neumann 1
PMCID: PMC1736691  PMID: 10567493

Abstract

OBJECTIVES—Haemangioblastoma of the CNS occurs as a sporadic entity and as a manifestation of the autosomal dominant von Hippel-Lindau disease with the major additional components retinal angioma, renal cancer, and pheochromocytoma. Genetic testing for germline mutations predisposing to von Hippel-Lindau disease has been available since identification of the VHL tumour suppressor gene. The impact of this testing was evaluated in patients with haemangioblastomas seen in this centre.
METHODS—A register and database of patients with symptomatic haemangioblastomas for the last 15 years was evaluated. The VHL gene was analysed by the SSCP method for all exons and Southern blotting for mutations and deletions of the gene.
RESULTS—141 patients with haemangioblastoma of the CNS were registered. In 81 patients (57%) there was a disease predisposing germline mutation including eight novel mutations. Population related calculation of patients from the administrative district of Freiburg disclosed VHL germline mutations in 22% of the patients with haemangioblastoma. Analysis of mutation carriers for clinical information suggestive of the syndrome showed (1) a positive family history of a brain tumour in 50%, (2) a history for the patient of extracranial manifestations in 36% (retinal angioma 30%, pheochromocytoma 6%), and (3) 19% presenting with multiple brain tumours when first admitted. By genetic testing of haemangioblastoma patients without any indications of von Hippel-Lindau disease mutation carriers were identified in 14%. Sensitivity of VHL germline testing was 86%.
CONCLUSIONS—DNA analysis for VHL germline mutations is clearly superior to clinical information in the diagnosis of von Hippel-Lindau disease. Although the percentage of von Hippel-Lindau disease associated haemangioblastoma decreases after the fourth decade of life and is infrequent in patients without other symptomatic lesions and a negative family history, it is recommended that every patient with CNS haemangioblastoma should be screened for von Hippel-Lindau disease germline mutations. This provides the key information and enables screening for extraneurological tumours of the patients and investigations of the patient's family to ameliorate management of von Hippel-Lindau disease.



Full Text

The Full Text of this article is available as a PDF (87.6 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Budowle B., Chakraborty R., Giusti A. M., Eisenberg A. J., Allen R. C. Analysis of the VNTR locus D1S80 by the PCR followed by high-resolution PAGE. Am J Hum Genet. 1991 Jan;48(1):137–144. [PMC free article] [PubMed] [Google Scholar]
  2. Béroud C., Joly D., Gallou C., Staroz F., Orfanelli M. T., Junien C. Software and database for the analysis of mutations in the VHL gene. Nucleic Acids Res. 1998 Jan 1;26(1):256–258. doi: 10.1093/nar/26.1.256. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Gnarra J. R., Tory K., Weng Y., Schmidt L., Wei M. H., Li H., Latif F., Liu S., Chen F., Duh F. M. Mutations of the VHL tumour suppressor gene in renal carcinoma. Nat Genet. 1994 May;7(1):85–90. doi: 10.1038/ng0594-85. [DOI] [PubMed] [Google Scholar]
  4. Lamiell J. M., Salazar F. G., Hsia Y. E. von Hippel-Lindau disease affecting 43 members of a single kindred. Medicine (Baltimore) 1989 Jan;68(1):1–29. doi: 10.1097/00005792-198901000-00001. [DOI] [PubMed] [Google Scholar]
  5. Latif F., Tory K., Gnarra J., Yao M., Duh F. M., Orcutt M. L., Stackhouse T., Kuzmin I., Modi W., Geil L. Identification of the von Hippel-Lindau disease tumor suppressor gene. Science. 1993 May 28;260(5112):1317–1320. doi: 10.1126/science.8493574. [DOI] [PubMed] [Google Scholar]
  6. Maddock I. R., Moran A., Maher E. R., Teare M. D., Norman A., Payne S. J., Whitehouse R., Dodd C., Lavin M., Hartley N. A genetic register for von Hippel-Lindau disease. J Med Genet. 1996 Feb;33(2):120–127. doi: 10.1136/jmg.33.2.120. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Neumann H. P. Basic criteria for clinical diagnosis and genetic counselling in von Hippel-Lindau syndrome. Vasa. 1987;16(3):220–226. [PubMed] [Google Scholar]
  8. Neumann H. P., Bender B. U. Genotype-phenotype correlations in von Hippel-Lindau disease. J Intern Med. 1998 Jun;243(6):541–545. doi: 10.1046/j.1365-2796.1998.00336.x. [DOI] [PubMed] [Google Scholar]
  9. Neumann H. P., Eggert H. R., Weigel K., Friedburg H., Wiestler O. D., Schollmeyer P. Hemangioblastomas of the central nervous system. A 10-year study with special reference to von Hippel-Lindau syndrome. J Neurosurg. 1989 Jan;70(1):24–30. doi: 10.3171/jns.1989.70.1.0024. [DOI] [PubMed] [Google Scholar]
  10. Neumann H. P., Lips C. J., Hsia Y. E., Zbar B. Von Hippel-Lindau syndrome. Brain Pathol. 1995 Apr;5(2):181–193. doi: 10.1111/j.1750-3639.1995.tb00592.x. [DOI] [PubMed] [Google Scholar]
  11. Stolle C., Glenn G., Zbar B., Humphrey J. S., Choyke P., Walther M., Pack S., Hurley K., Andrey C., Klausner R. Improved detection of germline mutations in the von Hippel-Lindau disease tumor suppressor gene. Hum Mutat. 1998;12(6):417–423. doi: 10.1002/(SICI)1098-1004(1998)12:6<417::AID-HUMU8>3.0.CO;2-K. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Neurology, Neurosurgery, and Psychiatry are provided here courtesy of BMJ Publishing Group

RESOURCES